Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true and openWorldHint=false, so the safety profile is covered. The description adds meaningful behavioral context beyond annotations by disclosing live-registry scope, free daily allowance, and paid access via x402 or X-API-KEY. It does not specify how many recent trials are returned, but that is a minor gap.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is a single front-loaded sentence that names the returned data, followed by a compact parenthetical on billing. There is no redundant prose, though the billing parenthetical is dense.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Because there is no output schema, the description compensates well by naming the returned aggregates and NCT links. Missing details such as the limit on 'most recent' trials are minor for this one-parameter read-only tool.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The sole parameter, slug, is fully documented in the schema as 'Peptide slug'. The description adds no further semantics such as format or examples, so the baseline of 3 applies given 100% schema description coverage.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

The description names a specific resource, the ClinicalTrials.gov registry landscape, and enumerates the returned aggregates: total studies, phase/status counts, active-study count, and recent trials with NCT links. It is clear about what the tool returns, but it does not explicitly distinguish itself from sibling get_trials.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

There is no explicit when-to-use guidance and no named alternative such as get_trials. The only additional context is pricing, so an agent must infer that this is the overview tool rather than a detailed trial search.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.